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Abstract 
Using a novel molecular design approach, we have prepared a thermo-responsive supramolecular 
polyurethane as a matrix material for use in drug eluting implants. The dynamic supramolecular 
polyurethane (SPU) is able to self-assemble through hydrogen bonding and π-π stacking interactions, 
resulting in an addressable polymer network with a relatively low processing temperature. The 
mechanical properties of the SPU demonstrated the material was self-supporting, stiff, yet flexible thus 
making it suitable for hot-melt extrusion processing, inclusive of related 3D printing approaches. Cell-
based toxicity assays revealed the SPU to be non-toxic and therefore a viable candidate as a 
biocompatible polymer for implant applications. To this end, the SPU was formulated with paracetamol 
(16 %w/w) and 4 wt% or 8 wt% poly(ethylene glycol) (PEG) as an excipient and hot melt extruded at 
100 °C to afford a 3D printed prototype implant to explore the extended drug release required for an 
implant and the potential manipulation of the release profile. Furthermore, rheological, infra-red 
spectroscopy, powder X-ray diffraction and scanning electron microscopy studies revealed the chemical 
and physical properties and compatibility of the formulation components. Successful release of 
paracetamol was achieved from in vitro dissolution studies and it was predicted that the drug would be 
released over a period of up to 8.5 months with hydrophilic PEG being able to influence the release 
rate. This extended release time is consistent with applications of this novel dynamic polymer as a drug 
eluting implant matrix. 
 
Introduction 
Investigating new functional excipient materials for local or systemic delivery of drugs is of ongoing 
interest.1 Such materials can lead to a range of benefits that can include improved efficiency of drug 
delivery, reduced toxicity and side effects and increased patient compliance.2 A key consideration when 
designing implantable drug delivery devices is the mechanism(s) and hence kinetics by which the 
desired drug is released. This can for example, be through physical degradation of a matrix, desorption 
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from a matrix surface, diffusion of the drug from within a matrix, or cleavage of a chemical bond to 
liberate the free drug.3 The ideal release time can range from hours to months depending on the 
condition being treated, the active ingredient, and the route of delivery and it is hence desirable that 
release rate is relatively easily manipulated via any newly developed matrix material. 
Materials developed for potential drug delivery applications range from porous materials,4 such as 
metal-organic frameworks,5,6 to polymers and gels7–11 which release the drug upon exposure to a 
suitable stimulus (e.g. pH and temperature).12–14 Polymeric systems typically comprise of 
polyurethanes,15 poly(caprolactone),16 poly(dimethylsiloxane),17 poly(lactic acid)18 and more 
extensively polyethylene glycol (PEG).13,19–22 Additionally, blends of different classes of polymers have 
been used22–24 and are employed to modify or tune release rates and profiles through a combination of 
the individual components properties. In the majority of polymeric drug delivery implant systems, 
release occurs upon degradation (surface or bulk) of the polymer matrix, resulting in increased surface 
area and subsequent drug release.25 A prominent example of this is the slow hydrolysis of carbamate 
motifs within polyurethanes which makes them suitable for long-term drug release in implants.21 This 
rate of bond cleavage and hence drug release can be tuned by blending polymers with different 
degradation rates.  
One new approach being investigated to produce different types of solid dosage forms is to deposit the 
formulation using additive manufacturing processes such as 3D printing of solutions via ink-jet 
technologies26 and solids by extrusion techniques.27 The later has shown promise in the 3D printing of 
well-known pharmaceutical materials, owing to similarities with traditional processing methods such 
as hot-melt extrusion.28 However, high processing temperature (≥180 °C) involved in this method, 
constraint the components that can be used to formulate pharmaceuticals.29,30 We offer a new approach 
to the formation of the solid implant from extrusion-based approaches at relatively mild temperatures. 
Herein, a dynamic supramolecular polyurethane (SPU) is reported which is able to self-assemble 
through hydrogen bonding and π-π stacking interactions,31 giving rise to thermally reversable material 
properties.32–34 The thermally addressable nature of the SPU makes it an ideal candidate for hot-melt 
extrusion, inclusive of 3D printing approaches, as the melt viscosity is in a suitable range for printing 
and a stiff, yet flexible structure is rapidly produced upon cooling.35 The relatively low temperature 
required to dissociate the supramolecular interactions, and thus deposit the material, may also widen 
the range of actives available to be formulated as a result of the mild processing conditions preventing 
thermal degradation. This lower operating temperature could address one of the main obstacles 
regarding extrusion of pharmaceutical formulations. Additionally, the release profile of a drug 
(paracetamol) can be modulated and enhanced by co-formulating with PEG,36,37 which is a regulatory 
approved and commonly used as an excipient in pharmaceutical and personal care applications. As a 
widely used pain-killer, it may be advantageous to incorporate paracetamol into an implant (e.g. for 
knee and joint replacement applications). The extrusion 3D printing of SPU-PEG-paracetamol 
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formulations to produce robust constructs which demonstrated suitable mechanical performance as well 
as biocompatibility is reported herein. Drug release from the printed formulations was evaluated via in 
vitro studies and the extrapolation of this data predicted that a release duration of 5 to 8.5 months would 
be achievable with the formulations; a timescale range that is consistent with many implant applications. 
There is clear potential to alter release rates further through modification of the formulation by varying 
the percentage of PEG or its molecular weight. 
 
Results and Discussion 
In order to create a prototype biomedical implant-style device which can be fabricated by hot-melt 
extrusion 3D printing, a thermally reversible polymer with a melting point below 140 °C (as dictated 
by the printer being used) was required. By harnessing the reversible nature of the supramolecular 
recognition motifs, the disassembly of the polymer network could be thermally triggered in the print-
head before being extruded onto the substrate surface (Figure 1). Upon cooling the recognition motifs 
are able to reassemble, yielding a mechanically robust object. Furthermore, polyurethanes often afford 
flexible materials which may be of benefit for patient comfort and welfare in addition to possibly being 
desirable in the method of deployment.    
 
Figure 1: Schematic representation of the 3D printing of the prototype drug-release implant comprising of a 
dynamic self-assembling polyurethane, PEG and model drug (paracetamol). 
 
Polymer Synthesis  
To realise an implantable and potentially personalisable drug delivery device, an appropriate 
supramolecular recognition motif was required. To this end, a hydrogen bonding and π-π stacking end-
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group, namely N-(4-methoxybenzyl)-1-(4-nitrophenyl)methanamine31 1 was identified as a suitable 
assembly motif and was synthesised (Scheme S1) via the formation of the imine and subsequent 
reductive amination (see Figure S1 and Figure S2 for characterisation). To prepare the supramolecular 
polymer, an apolar hydrogenated polybutadiene (Krasol HLBH-P 2000, molecular weight as 
received = 2 kg mol-1) polyol 2 as a viscous liquid  was end-capped with 4,4’-MDI 3 at 80 °C in the 
bulk38,39 to afford the pre-polymer 4 which was then terminated in solution (THF) by the recognition 
motif 1 (Scheme 1). The purified supramolecular polyurethane SPU1 was then afforded by multiple 
precipitations into methanol from THF. To confirm the successful synthesis of SPU1, NMR 
spectroscopy was undertaken (Figures S3-S5). 1H NMR spectroscopy (Figure S3) revealed the 
appearance of the characteristic methylene resonances adjacent to the newly formed urethane (4.15 
ppm) and urea (4.70 and 4.45 ppm) moieties. In addition, urea and urethane carbonyl resonances were 
observed at 159.0 ppm and 156.0 ppm by 13C NMR spectroscopy (Figure S4). IR spectroscopic analysis 
(Figure S6) confirmed the disappearance of the characteristic isocyanate stretch at 2340 cm−1 and the 
appearance of carbonyl stretches at 1708 and 1646 cm-1 corresponding to the newly formed urethane 
and urea bonds, respectively. Additionally, N-O stretches were observed at 1512 cm-1 and 1462 cm-1, 
assigned to the nitro group in the self-assembly motif and thus further confirming the incorporation of 
the end-group in the supramolecular polyurethane. Analysis of SPU1 by GPC (Figure S7) revealed a 
bimodal distribution, attributed to chain extension within the polyurethane, with a Mn of 6100 Da and 
Đ = 2.06, corresponding to approximately 2 repeat units per polymer chain.34 This is in close agreement 
with the integration analysis carried out by 1H NMR spectroscopy. The thermal characteristics of the 
polymer were also probed using differential scanning calorimetry (Figure S8) which revealed a 
Tg at -47.8 °C, which can be attributed to the soft domain of the phase separated supramolecular 
polymer, comprising of the hydrogenated polybutadiene. A second, less pronounced, Tg was observed 
at 19.45 °C which relates to the hard domains formed from hydrogen bonding motifs. These results are 
in good agreement with structurally related SPUs which demonstrate two thermal transitions.31,32,34 
Furthermore, the temperature range of Tgs of the bulk and self-assembled components indicated that the 
polymer was relatively malleable at room temperature and appropriate for use as a biomedical device 
produced by hot-melt extrusion printing. 
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Scheme 1: Synthesis of the supramolecular polyurethane SPU1 by chain-extension of the polyol 2 with a 
diisocyanate 3 to yield the pre-polymer 4 which was subsequently terminated with recognition motif 1. 
 
In order to assess the suitability of the supramolecular polymer for use in a biomedical device, films 
were required for analysis prior to 3D printing. To achieve this, the polymer was dissolved in the 
minimum amount of THF before drop casting onto PTFE moulds. The solution was left to dry under 
ambient conditions for 24 hours before drying under vacuum at 80 °C for a further 48 hours. Critically, 
SPU1 afforded a malleable elastomeric material (Figure S9) in contrast to the viscous hydrogenated 
polybutadiene precursor 2 as a result of the self-assembly of hydrogen bonding motifs and phase 
separation.40–44  
To explore the thermal responsive nature of the supramolecular polyurethanes, variable temperature IR 
spectroscopic analysis (VT-FTIR) was conducted (Figure S10) between 20 and 160 °C.45,46 A strong 
absorbance for both the free (1730 cm-1) and hydrogen-bonded (1710 cm-1) carbonyls units relating to 
urethane groups was observed, in addition to the ordered hydrogen bonded urea carbonyl moieties 
(1655 cm-1) and bound NH groups (3313 cm-1) in SPU1 at room temperature. Indeed, the intensity of 
the urethane, urea and NH absorbance bands were seen to weaken and/or shift with increased 
temperature,38 as a result of dissociation of the hydrogen bonds which was consummate with a new 
absorbance at 3440 cm-1, indicative of free NH bonds. Most notably, the absorbance corresponding to 
hydrogen bonded urethanes could be seen to diminish and coalesce with the adjacent free carbonyl 
signal. To further quantify the disruption of the hydrogen bonding network at elevated temperatures, 
the area of the hydrogen bonding urethane carbonyls and NH absorptions were calculated (Figure S11) 
by deconvoluting and fitting the absorbance bands. Over the temperature regime investigated, hydrogen 
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bonded urethane carbonyls demonstrated a ca. 40 % reduction in abundance, whilst the prevalence of 
free urethane carbonyls increased by ca. 40 %. Additionally, a decrease of ca. 45 % in absorbance area 
was observed in hydrogen bonding NHs. Additionally, upon cooling, the intensity of signals relating to 
hydrogen bonding motifs were fully restored, demonstrating the thermally dynamic character of the 
polymer network.   
 
Biocompatibility Studies  
To fabricate a safe drug delivery device, it is essential that the polymer be biocompatible. It has been 
reported
47
 that polyurethanes are biocompatible, and as a consequence have been utilised in designing 
drug delivery systems. Moreover, we have demonstrated that a structurally related polyurethane with 
morpholine end groups has shown biocompatibility with human fibroblasts.
32 In the current system 
where the ratio of the end group to the total polymer did not exceed (8 mol%), the terminal groups have 
been modified in order to obtain a polymeric material with desirable physical characteristics to enable 
it to be used in hot-melt extrusion printing. As a first step in establishing the potential of SPU1 in this 
regard, the cytotoxicity of the polyurethane films was evaluated. Liquid extracts from the polymeric 
films were used to determine the biocompatibility of the polymeric films by an MTT assay. To achieve 
this, mouse fibroblasts (L929), immortalised cells used routinely to evaluate biocompatibility, were 
exposed to the liquid extracts. The polyurethane was found to be non-toxic, as cell viability was in 
excess of 94% after exposure to undiluted (100%) liquid extracts from the polymer (Figure 2). 
Importantly this is not significantly different from the negative control and hence SPU1 was a potential 
candidate for 3D printing of a biomedical device. Interestingly, the exchange of the end groups, from 
morpholine to N-(4-methoxybenzyl)-1-(4-nitrophenyl)methanamine resulted in a non-cytotoxic 
polymer. These results are in good agreement with our previously reported data, in which a 
poly(caprolactone)-derived supramolecular polyurethane with the analogues N-(4-methoxybenzyl)-1-
(4 nitrophenyl)methanamine end groups was found to be non-toxic.
48 
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Figure 2: Cytotoxicity of liquid extracts from the Medium, supramolecular polyurethane (SPU1) at different 
dilutions (100%, 75%, 50%, 25%), positive control (PU-ZEDC) and negative control (PE), both at 100%. Data 
are presented as mean ± s.e.m. Statistical significance with respect to untreated cells (medium) was determined 
by ANOVA followed by Bonferroni post hoc test (* = TBC - P < 0.05; ns = non-significant). 
 
Polymer Formulations and Analysis  
In order to formulate a drug delivery device with effective rates of release in addition to good 
processability, a formulation was developed comprising of the supramolecular polyurethane and PEG. 
A commercially available PEG (Mw as received = 20 kg mol
-1) was selected as an excipient to modify 
the rate of release of the active from the formulation and further tune the extrusion characteristics of the 
polymer blend.35 Our previous studies have revealed that less than 8 wt% of PEG is able to modify the 
release rate of a dosage form whilst also having a positive contribution to the printability of the 
formulation.49 Paracetamol was selected as the model drug and formulated at 16 wt%. We have 
previously used paracetamol in a number of oral-dosage form 3D printing studies, illustrating an ability 
to achieve formulations that meet Pharmacopeia standards of manufacture, e.g. weight uniformity, 
hardness, friability etc.50,51  
Formulations for 3D printing were prepared by blending SPU1 and PEG (20 kg mol-1) in ethyl acetate 
(0.15 mL g-1) prior to the addition of paracetamol to yield a homogeneous mixture (Table 1) before 
removing the solvent in vacuo.  
Table 1: Composition of the formulations F1 and F2.  
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In order to probe the effect of PEG on the thermoresponsive supramolecular polyurethane, VT-FTIR 
spectroscopic analysis was conducted between 20 °C to 160 °C (Figure S10). The formulations F1 and 
F2 demonstrated significant decreases in absorbances associated with hydrogen bonding (bound NH - 
3313 cm-1 and urethane carbonyls - 1710 cm-1) and a concurrent increase in free urethane (1740 cm-1) 
and free NH (3440 cm-1) absorbances. Additionally, the stretch at 1655 cm-1, corresponding to ordered 
hydrogen bonded urea carbonyl units (1655 cm-1) proceeded to shift to a higher wavenumber (1670 cm-
1) upon heating, indicating dissociation of hydrogen bonding of the urea moieties. Whilst the rate of 
dissociation of hydrogen bonding is approximately equivalent in SPU1, F1 and F2 (Figure S11), the 
composition of hydrogen bonding moieties differs between the neat polyurethane and the formulation. 
The hydrogen bonded NH moieties remained the predominant relative to the carbonyl moieties, 
however, the relative prevalence of hydrogen bonding carbonyls was observed to have decreased in F1 
and F2 when compared to SPU1.       
To study the physical properties of the polymer formulations as related to assessing their suitability for 
printing and potential long-term stability as implants, films were prepared as previously described with 
the addition of the relevant weight percentage of PEG. The polymer films were then annealed in the 
oven for 72 hours at 80 °C until dry. To assess the thermal characteristics of the polyurethane SPU1 
and formulations F1 and F2 and rheological analysis of film was undertaken (Figure 3). In all instances, 
the physical properties of the polymer were governed by the elastic character of the materials, in the 
low temperature regime (ca. 0-35 °C), as demonstrated by the storage modulus (G’) being in excess of 
the loss modulus (G”). Upon further heating, G’ and G” gradually decreased as a result of the 
dissociation of the supramolecular polyurethane network and shift in equilibrium towards the unbound 
state. In contrast, the rheological behaviour of the hydrogenated polybutadiene 2 is dominated by the 
viscous character of the polymer through all temperature regimes, as exemplified by a constant phase 
angle of ca. 90° upon heating (Figure S12). When considering SPU1 alone (Figure 3a), the phase angle 
is initially less than 45 ° at low temperatures, indicating the material properties are predominantly elastic 
in nature. At 38 °C, the phase angle crosses 45 ° and therefore viscous behaviour governs the properties 
of polyurethane at temperatures in excess of this. By increasing the PEG content, the temperature at 
which the cross-over between G’ and G” occurred was observed to increase as a result of the PEG 
excipient retarding the transition from elastic to viscous behaviour within the system (Figure 3b and 
3c). Therefore, the incorporation of PEG in the formulation increased the temperature of the cross-over 
point, shifting this away from core body temperature (37 °C). In doing so, this may contribute to the 
control mechanism of drug release using the PEG as well as making the resulting implant more 
mechanically robust under normal operating temperatures within the body.    
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Figure 3: Rheological behaviour of A) SPU1, B) F1 and C) F2 with respect to temperature. 
 
To further explore the morphology of the supramolecular polyurethane 1 and the phase behaviour of 
the PEG in Formulations F1 and F2, SAXS analysis was conducted (Figure S13). SPU1 exhibits typical 
micro-phase separation behaviour as confirmed by the Bragg peak centred at 73.6 Å which arises from 
immiscibility of the polar hard (self-assembling) and apolar soft (polymer backbone) domains. PEG 
displayed Bragg peaks at 154.6 Å and 84.9 Å, respectively whilst the addition of PEG to the 
supramolecular polyurethane to yield formulations F1 and F2 for 3D printing resulted in shifts to lower 
domain spacing (F1 = 66.9 Å, F2 = 69.3 Å). Interestingly, no apparent diffraction peaks attributed to 
PEG were observed in the formulations. This data suggests that the PEG within the formulation was 
thoroughly mixed into the phase separated polyurethane architecture through incorporation into the 
polar hard domains. Furthermore, this data is supported by VT-FTIR spectroscopy (Figure S10 and 
Figure S11) which suggests that PEG is incorporated into the self-assembling polyurethane matrix as 
demonstrated by weakening of the hydrogen bonding carbonyl absorbances relative to the neat SPU1.   
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Tensile testing was carried out to further understand the mechanical characteristics of the polymer 
formulations (Figure 4). From the cast films, strips of polymer (ca. 40 mm × 5 mm × 1 mm) were 
produced for analysis, by extended to failure, the corresponding mechanical properties were calculated 
from the individual stress–strain curves (Table 2). 
  
Figure 4: Stress/strain curves for drop-cast films of the supramolecular polyurethane (SPU1) and formulations 
for 3D printing (F1 & F2) as cast from solution. 
 
The supramolecular polyurethane exhibited the greatest ultimate tensile strength (0.37 MPa), Young’s 
modulus (2.34 MPa), modulus of toughness (0.67 MPa) and elongation at break (500 %). In agreement 
with rheological studies, the incorporation of 4 wt% PEG to the formulation (F1) dramatically reduced 
the mechanical properties of the formulation. A loss of approximately 50 % of the ultimate tensile 
strength (0.20 MPa), 20 % of the Young’s modulus (1.87 MPa) and 69 % of the modulus of toughness 
(0.21 MPa) was observed. Furthermore, the elongation at break was observed to have decreased to 
210 %, a reduction of 290 % when compared to SPU1. The decrease in mechanical performance was 
attributed to the PEG excipient interrupting the hydrogen bonding network and thus reducing self-
assembly between the hydrogen bonding motifs. This was corroborated by SAXS data (Figure S13) 
collected from films of the formulation which suggested that PEG was thoroughly mixed into the phase 
separated polymer matrix, signified by the omission of diffraction peaks relating to PEG. It is likely 
that the polar PEG molecules would have migrated to the polar self-assembling hard domains, thus 
interrupting the self-assembly. Similar reductions in mechanical performance were also observed in F2. 
Whilst a reduction in the mechanical properties were observed through the addition of PEG to the 
supramolecular polymer matrix, the resulting properties were still within the printable parameters range 
for hot-melt extrusion 3D printing of a geometrically well-defined object that could be considered for 
future development into an implant and therefore this material was utilised in the development of test 
structures.                                                 
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Table 2: Tensile data for the neat supramolecular polymer (SPU1) and formulations containing PEG (F1 & F2). 
 
 
3D Printing and Analysis of Prototype Implants   
To produce a prototype implant, a bar geometry (30 mm × 3 mm × 2.5 mm), similar to that used for 
some contraceptive implants, was designed using computer aided design (CAD) before being converted 
into layers ready for 3D printing. The formulations were loaded into an aluminium extrusion printing 
cartridge and placed in a Cellink INKREDIBLE printer. The formulations were subsequently deposited 
with control over parameters such as extrusion pressure, temperature, printing layer height, printing 
speed and material infill (see Supplementary Videos 1 and 2). Bar samples were then printed to evaluate 
the spatial definition and composition of the materials (Figure 5). Drug-free formulations were also 
printed as controls using the same conditions for materials testing.  
 
Figure 5: Side-on and end-on view images of the 3D printed bars of A: F1 (4% PEG) and B: F2 (8% PEG). 
The dimensions and masses of the prototype implants (N = 10 bars) were then analysed (Table 3) to 
assess the resolution and reproducibility of the printing process. Less than 2% deviation was observed 
 
Ultimate Tensile 
Strength (MPa) 
Youngs Modulus 
(MPa) 
Modulus of 
Toughness (MPa) 
SPU1 0.37 ± 0.02 2.34 ± 0.27 0.67 ± 0.05 
F1 (4% PEG) 0.20 ± 0.01 1.87 ± 0.10 0.21 ± 0.08 
F2 (8% PEG) 0.20 ± 0.03 1.52 ± 0.13 0.24 ± 0.06 
 
A
B
 12 
in the length and thickness for both F1 and F2 (Table S1), indicating good printability of the polymer 
formulations. The widths of the printed bars were also analysed and were revealed to be slightly more 
variable (F1 = ± 4%, F2 = ± 3%), however, this still demonstrated good reproducibility of the printed 
prototype implants.  The weight of individual printed bars was also measured (Table S2) and analysis 
showed that the printed implants comprised of F1 comply with the United States Pharmacopeia (USP) 
specification (±7.5% deviation).52 Larger variations up to 9.5% were noted for the bars printed from F2 
which may relate to the increased PEG content and its effect on printability, but this remains to be 
determined.  
Table 3. A summary of the dimensions, print parameters and masses of printed bar implants (n=10 for all 
measurements). 
 
 
To confirm the incorporation of the drug in the formulation and assess its stability during the printing 
process, IR spectroscopy (Figure 6a) was conducted on the pure components (SPU1, PEG, and 
paracetamol) and the printed formulations (F1 and F2). From the cast film of SPU1, both urethane 
(1708 cm-1) and urea (1644 cm-1) carbonyl stretches were observed..31 Sharp absorptions at 1521 cm-1 
and 1462 cm-1 were attributed to the N-O stretch arising from the nitro functionalised aryl group of the 
terminal self-assembly motif in the polymer. A characteristic N-H stretch from the urea was also 
identified at 3323 cm-1, and N-H plane deformation and C-H stretch were identified at 1523 cm-1 and 
2921 cm-1, respectively. An out of plane C-H bend was also observed around 815 cm-1. Two strong 
absorptions, centred at 2882 cm-1 and 1096 cm-1 were observed in PEG and were attributed to C-H 
stretching and the C-O stretching within the polymer, respectively.53 Finally, an N-H stretch 
(3323 cm-1), out of plane C-H bend (836 cm-1), carbonyl adsorption bands (1650 cm-1) and N-H plane 
deformation at 1561 cm-1 were observed in paracetamol in addition to the expected O-H stretch at 3161 
cm-1.54  
IR spectroscopy of the 3D printed formulations (F1 and F2) were then analysed to assess the stability 
of the components. Indeed, N-H stretches were observed at 3323 cm-1 for F1 and 3315 cm-1 for F2, 
comparable to that seen in pure SPU1 and paracetamol. A carbonyl stretch was observed at 1654 cm-1 
in both F1 and F2 relating to paracetamol in addition to an adsorption at 1709 cm-1 which was attributed 
to the carbonyl moiety from SPU1. Additionally, N-O stretches were observed at 1516 cm-1 and 1462 
cm-1, further confirming the presence of the supramolecular polymer in formulations F1 and F2. The 
  F1 F2 
3D model geometry Bar 
3D model dimension (mm) 30 (L) x 3 (w) x 2.5 (H) 
Length (L)* 29.58 ± 0.19 29.59 ± 0.14 
Width (W)* 3.11 ± 0.06  3.17 ± 0.03 
Thickness (H)* 2.54 ± 0.02 2.71 ± 0.01 
Mass (g)* 0.224 ± 0.0036 0.212 ± 0.0108 
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N-H plane deformation peaks from both paracetamol and SPU1 overlap and can be found at 1514 cm-1 
in both F1 and F2. The O-H stretch of paracetamol was not apparent in F1 and F2, possibly as a result 
of hydrogen bonding between the active and the polymer matrix.  
Powder X-ray diffraction (PXRD) of the pure components and the two printed formulations was also 
performed in order to examine the state of the dispersed drug in the final formulations (Figure 6b). The 
SPU1 diffraction pattern exhibits a broad halo, indicating that the polymer is amorphous. This is in 
accordance with data previously reported by Feula et al.17 In contrast, the diffraction pattern of the PEG 
excipient suggests that this material is at least in-part crystalline, as indicated by the two broad 
diffraction signals.31 The PXRD pattern of pure paracetamol matches that of crystalline form I 
previously reported.55 After formulation and printing, there is no evidence of a phase transformation of 
paracetamol in the formulations, F1 and F2. Owing to the low percentage composition of PEG in F1 
and F2, nothing definitive can be said about the crystallinity of PEG in these formulations after printing, 
based on the PXRD data alone. However, as there is no evidence of any change in the crystalline form 
of the paracetamol in the printed formulations F1 and F2, this suggests that the printing process does 
not alter or damage the constituent components of the formulations. This was further studied by DSC 
analysis of SPU1, F1 and F2 (Figure S8). Two glass transitions at ca. -47 °C and ca. 0 °C, typical of 
phase separated polyurethane are noted.33,56 Although, no meaningful changes in thermal transition 
temperatures were observed, a less intense melting peak at ca. 57 °C that corresponds to PEG was 
present in the thermograms of the printed formulations. These results suggest that the high shear and 
temperature experienced by the formulation in the hot-melt extrusion 3D printing process lead to a more 
efficient blending of SPU1 and PEG and therefore, a loss in PEG crystallinity. 
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Figure 6: A) FTIR spectra and B) PXRD patterns of pure SPU1, PEG 20 kg mol-1, paracetamol and the printed 
bars of F1 and F2. 
 
To explore the effect of 3D printing on the formulation, additional SAXS experiments were conducted. 
Scattering patters were collected of the printed formulations, F1 and F2, and compared to the cast 
analogues (Figure S14). A decrease in domain sizes (ca. 4 Å shift) was observed in both formulations 
as a consequence of the 3D printing process. Although a small change, this may be as a result of the 
thermal and shear processes associated with 3D hot-melt extrusion printing annealing the polymer 
formulation and reducing the size of the domains though enhanced mixing of the two polymer phases.    
It was noted that after a week, the surface of the printed prototype implant appeared to smoothen slightly 
(Figure S15), and visually the layers appeared to become more homogeneous as a result of creep. To 
monitor the effects of creep on the mechanical properties of drug-free formulations, 3D printed samples 
were aged under ambient conditions for 7 days. To study the effect on rheological behaviour, a 
frequency sweep at 25 °C was performed in the linear viscoelastic region and between 0.01 Hz and 
100 Hz (Figure S16). It was noted that the rheological properties did not show any significant 
improvement when considering either processing technique. The rheological properties of the 3D 
printed samples over time were also compared with a sample prepared by drop-casting (Figure S17). 
Interestingly, whilst the drop cast films do appear to be a good model for the 3D printed disks, the 
printed objects exhibited a modest increase in modulus (cast = 4.5×104 Pa, printed = 1×105 Pa). It is 
believed that the elevated temperature, combined with high sheer forces imparted on the polar PEG and 
apolar SPU components of the formulation during printing resulted in a more intimate mixture of the 
polymers (and hence stiffer) when compared to the drop cast sample.  
To further examine the effects of creep on the mechanical properties of the 3D printed drug-free 
formulations, the printed bars (ca. 40 mm × 5 mm × 0.7 mm) were elongated to break, and stress/strain 
profiles recorded (Figure S18). Interestingly, the ultimate tensile strength (Figure S19a) of the printed 
material was seen to reduce by approximately 20% in F1 and 45% in F2 when compared to the pure 
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polymer film prepared by drop-casting (Table S1), indicating that 3D printing does not fully translate 
the materials ability to withstand loads as a result of voids and poor interlayer adhesion compared to 
the homogeneous drop-cast films.  Furthermore, although interlayer contact appears to improve visually 
over time, the ultimate tensile strength remains approximately constant between printing and day 7 for 
both formulations (F1 and F2). The Young’s modulus (Figure S19b) was approximately equivalent 
when comparing 3D printed and drop-cast data for formulations F1 and F2 (Table S3), revealing that 
along the axis of printing and elongation, the polymers properties were unaffected by formulation and 
processing. An upward trend was observed in Young’s modulus over time which was attributed to the 
dynamic nature of the supramolecular polymer within the printed formulation. During the aging 
process, the printed layers undergo minor deformation as a consequence of thermal relaxion and 
reassembly of the supramolecular polymer in a lower energy regime.57 Thus, the printed objects which 
have undergone creep over time demonstrate a moderate increase in strength and are therefore more 
resistant to permanent deformation. This relationship was most pronounced in F1 where the percentage 
composition of PEG was at its lowest, allowing for better network reorientation over time.  
Although a slight decrease in the resolution of the printed object may occur, the deformation may result 
in enhanced mechanical properties by virtue of improved interlayer adhesion and increased contact area 
between printed layers. Mechanical analysis of creep by rheology and tensile testing can be correlated 
with rheological analysis of the cast materials (SPU1, F1 and F2: Figure 3) where the temperature at 
which G’ and G” was observed to cross (phase angle = 45°) is close to ambient temperature in all 
instances, thus allowing the dynamic supramolecular polymer to disassemble and reassemble slowly 
over extended timeframes.  
 
Drug release from the Printed Prototype Implants 
The initial rate of paracetamol release from the printed formulations was determined with HPLC. 
(Figure 7). The printed implants were found to exhibit similar release rates, with up to 2.5% paracetamol 
and 2% paracetamol were released for formulations, F1 and F2, respectively. With such low release 
levels fitting models to the such data to predict long-term release should be done with some caution. 
With this in mind, a first order release model was implemented to approximate the behaviour of the 
implants beyond 168 hours (Table S4). F1 and F2 are predicted to fully release the active over 8.5 
months and 5 months, respectively. This is, at the very least, indicative that suitable timescales for 
applications of these materials as implants will be achievable and that composition variations, such as 
PEG amount as here, can be used to tune release rate. In order for the material to be suitable for implant 
applications, it should robustly retain its designed shape. It should be noted that deformation of the 
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implants (Figure S20) was observed after dissolution testing; suggesting that further optimisation of the 
material may be needed.  
 
Figure 7: Release behaviour of paracetamol over 7 days from the printed formulations, F1 and F2. Data shown 
are average of 5 repetitions.  
 
SEM was used to characterise the morphology of the printed formulations (F1 and F2). Hot melt 
extrusion of both formulations gave rise to homogeneous mixtures of SPU1 and PEG in addition to 
well dispersed paracetamol within the polyurethane matrix as demonstrated by the absence of 
agglomerates and crystallites. To examine the effects of drug release on morphology, analysis was also 
carried out after 7 days of dissolution studies. A stark contrast in the structure of the printed formulations 
was observed after treatment with the dissolution media (Figure 8), resulting in a micro-porous network 
which was attributed to the leaching of the PEG excipient. As expected, the pores were more prominent 
in the F2 as a consequence of the increased loading of PEG in the formulation. Clearly, the size of these 
pores cannot be the only contributing factor to drug release as on the time-scales observed in our 
dissolution studies there is not a direct correlation with this microscopic observation and drug release. 
Many factors are likely to contribute to drug release, including pore connectivity, pore size distribution 
and exposed surface area and these remain a matter for future formulation optimisation studies. Whether 
these features would affect the integrity of the implant over longer timescales should also be considered 
and may explain the deformation of the implants (Figure S20).   
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Figure 8: SEM images of sample cross-section before and after the dissolution tests. 
 
Conclusions 
Through molecular design, we have prepared a thermo-responsive supramolecular polyurethane able to 
dissemble and assemble at a specific transition temperature and evaluated its potential biocompatibility 
and cytotoxicity. The mechanical properties of the SPU1 showed that the material is self-supporting 
and stiff, yet flexible. The material was therefore investigated as a candidate for 3D printed implant 
applications. In order to investigate the release characteristics, paracetamol (16 wt%) was dispersed into 
the SPU1 formulated with 4 wt% or 8 wt% PEG excipients to investigate the ability to manipulate drug 
release profile. Bar implants were then designed, and the formulations successfully 3D printed using a 
hot-melt extrusion printer from melt at 100 °C. 
The mechanical characteristics of the formulations were analysed which indicated that the material was 
a suitable matrix for hot-melt extrusion printing. The paracetamol in the printed implants was identified 
as form 1 by PXRD and there were no adverse effects observed in printing the active in the formulations 
after extrusion. HPLC was used to quantify drug release. From initial dissolution experiments, the 
release profiles were fit to a first-order drug release model. This approximation indicates that 36 mg of 
paracetamol would be released within upto 8.5 months depending on PEG loading. This slow and 
potentially controllable release profile is consistent with timescales desired and needs for optimisation 
for drug eluting implants. However, we note that deformation of the implants over course of dissolution 
characterization. Finally, SEM was used to examine the morphology of the printed implants before and 
after drug release. The transition temperatures of the SPU may need to be further considered and 
optimised for long term release applications. 
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Experimental  
Materials 
All reagents were purchased from Sigma Aldrich or Alfa Aesar and used as received with the exception 
of Krasol HLBH-P2000 (Mw as received = 2 kg mol
-1) [hydrogenated poly(butadiene)] which was 
supplied by TOTAL Cray Valley. Solvents were purchased from Fisher Scientific and used as received. 
Additionally, tetrahydrofuran (THF) was distilled from sodium and benzophenone prior to use, where 
anhydrous THF was needed. For cytotoxicity studies, polyurethane containing 0.1% (w/w) zinc 
diethyldithiocarbamate (PU-ZDEC) and polyethylene (PE) were obtained from Hatano Research 
Institute, Food and Drug Safety Center, Japan. Fetal bovine serum and streptomycin were purchased 
from Gibco™. 
Instrumentation and Methods 
Polymer Analysis 
1H NMR spectroscopy (400 MHz) and 13C NMR spectroscopy (100 MHz) were recorded with either a 
Bruker Nanobay 400, or Bruker DPX 400, using an appropriate deuterated solvent. Gel permeation 
chromatography (GPC) analysis was obtained by an Agilent Technologies 1260 Infinity systems in 
THF and polystyrene standards were used for calibration. Differential Scanning Calorimetry (DSC) 
thermograms were obtained using a TA DSC Q2000 adapted with a TA Refrigerated Cooling System 
90, using aluminium TA Tzero pans and lids. Thermal transitions were recorded using heating and 
cooling rates of 10 °C min-1 and 20 °C min-1, respectively. Tensile tests were carried out using AML 
instrumentsTM single column tensiometer. From each film 3 strips (5 mm × 40 mm × 1 mm) were cut 
and individual samples were located between the grips of tensile instrument and elongated at a rate of 
10 mm min−1 and the stress vs. strain curve recorded. The modulus of toughness was calculated by 
integrating the recorded plot to give the area under the curve. The trapezium rule was applied to 
calculate the area between zero strain to strain at break for each sample. The error reported is the 
standard deviation between the calculated areas of three repeats for each sample. Rheological 
experiments were carried out using a Malvern Panalytical Kinexus Lab+ fitted with a peltier plate 
cartridge and 8 mm parallel plate geometry. Cast samples were first heated to 60 °C applying 1 N of 
force to obtain good contact between the sample and geometry/plate. An amplitude sweep (between 
0.1-16 % at 1 Hz) and frequency sweep (0.01 - 100 Hz) was then conducted to determine the linear 
viscoelastic regime as determined by the software (Malvern rSpace). The sample was then heated from 
0 °C to 170 °C whilst recording the storage and loss moduli in oscillatory mode. To carry out rheology 
experiments on printed samples, they were loaded on the instrument at 25 °C and the amplitude and 
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frequency sweep experiments were conducted at the same temperature. Variable temperature infrared 
spectra were recorded with Perkin-Elmer Spectrum 100 FTIR spectrometer equipped with Specac 
variable temperature cell holder and Temperature Controller. To carry out the experiment, KBr disks 
containing 1 wt% of each sample were prepared. Briefly, 3.00 mg of each analyte was dissolved in 
minimum amount of THF and mixed with 300 mg KBr powder. The mixture was then dried completely 
under vacuum and grounded to achieve a fine powder which was then pressed to produce a disk. A pure 
KBr disk was also prepared following the same approach in order without adding a sample in order to 
collect the background. The carbonyl and NH regions of the collected spectra were fitted to Gaussian 
distributions. These were then used to calculate the area corresponds to each peak. The calculated areas 
are plotted in Figure S11. 
Biocompatibility Studies 
In vitro cell culture studies were performed using a mouse fibroblast cell line (L929, ECACC). Cells 
were cultured in Dulbecco’s modified eagle’s medium (high glucose) supplemented with 2 mM of 
L-glutamine, 10 % fetal bovine serum, penicillin (100 units mL-1) and streptomycin (0.1 mg mL-1). Cells 
were maintained in a 5% CO2 humidified atmosphere at 37 °C. Potential in vitro cytotoxicity effects of 
SPU1 were evaluated as follows. The polymeric films were incubated with tissue culture medium (3 
cm2 mL-1, for 24 hours) as previously reported.32 Polyurethane containing 0.1% (w/w) zinc 
diethyldithiocarbamate (PU-ZDEC) and polyethylene (PE) were used as positive and negative controls, 
respectively. After incubation, the polymeric films were removed and their liquid extracts (the culture 
media containing any materials leached from the polymeric films during the incubation) were either 
applied or diluted, where required, using the tissue culture medium prior to their application onto the 
cells. Cells were seeded in a 96 well plate at 1 × 104 cells per mL in tissue culture medium and allowed 
to adhere for 24 hours. The medium was then replaced with 100 µL of either: (a) the tissue culture 
medium, (b) liquid extracts from SPU1 at different dilutions (100, 75, 50, 25%) (c) liquid extracts of 
the positive control (PU-ZDEC) at (100%) or (d) liquid extracts of the negative control PE at (100%), 
and cells incubated with the extracts for 48 hours. All diluted liquid extracts were sterile filtered prior 
to their application onto the cells. After 43h incubation, a 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) solution (5 mg mL-1 in PBS) was added to the wells (20 µL per 
well) and cell viability assessed as previously reported.32 
Formulation Analysis 
Drug containing formulations for 3D printing were prepared in accordance with Table 1. Briefly, SPU1 
and PEG (20 kg mol-1) were dispersed in ethyl acetate (0.15 mL g-1) and the formulation heated to 
100 °C until homogenous. Paracetamol (acetaminophen) was then added to the translucent and yellow 
formulations and stirred under continued heating until evenly dispersed to yield pale yellow and opaque 
materials with 4 wt % PEG (F1) and 8 wt% PEG (F2), respectively. The solvent was then removed in 
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vacuo at 70 °C for 24 hours until constant mass was obtained. The formulations for 3D printing were 
loaded into an aluminium extrusion printing cartridge fitted with a sterile precision conical nozzle (I&L 
Biosystems Ltd., Seer Green, UK) with an inner diameter of 0.609mm (21G). A Cellink INKREDIBLE 
printer was used to print the formulations. The extrusion pressure and temperature were set as 3.0 bar 
(300kPa), 100 °C and 3.1 bar (310kPa), 105 °C for formulation F1 and F2 respectively, a printing layer 
height of 0.3 mm, printing speed of 10 mm s-1 and an infill of 100%. A bar geometry (30mm x 3mm x 
2.5mm) was designed using Blender computer graphics software. G-codes were then generated with 
Slic3r (version 1.3.0) with the optimised printing parameters stated above.  
Infrared spectra of pure paracetamol, SPU1, PEG 20 kg mol-1 and the two printed formulations (F1 and 
F2) were collected using a Perkin Elmer Frontier FTIR-ATR spectrometer between 4000 cm-1 and 
550 cm-1 with a scan resolution of 2 µm and a step size of 0.5 cm-1. The PXRD patterns of pure 
paracetamol, excipients (SPU1, and PEG) and the printed formulations (F1 and F2) were obtained at 
room temperature using a Bruker D8 Advance with DaVinci XRD instrument, setup in divergent beam 
mode running in Bragg-Brentano geometry and a Lynxeye 1D detector. A generator voltage of 40 kV 
was set, with a current of 40 mA. Samples were scanned over 2 theta range of 10° to 40 ° in a step size 
of 0.02 ° and time per step of 1 second. 
Small angle X-ray scattering (SAXS) data were collected using a Bruker Nanostar instrument with an 
Incoatec microfocus X-ray source operating at 45 kV. Scattering patterns were collected using a Vantec 
area detector (2048 × 2048 pixels) using silver behenate as a calibrant. 
Release Studies 
Dissolution testing of the printed implants was carried out using a Copely Scientific Dissolution Tester 
DIS 8000 with rotating USP I baskets according to USP specifications for paracetamol. Briefly, 0.05 M 
potassium phosphate dissolution media was prepared with potassium dihydrogen phosphate in ultra-
pure water (18.2 MΩ.cm) and adjusted to pH 6.8 with a 50 wt% sodium hydroxide solution. Testing 
was carried out at constant volume at 37 C in 900 mL of media. Five millilitre sample aliquots were 
removed at predetermined times (24 h, 48 h, 72 h, 144 h,168 h) and replaced with five millilitres of 
media at 37oC and filtered with a (0.45 µm Millex PTFE hydrophilic filter). Samples were then analysed 
with an Agilent HPLC Series 1260 Infinity system, equipped with a UV diode array detector. A 
wavelength of 243 nm was used to quantify the paracetamol. The mobile phase compositions were 80% 
ultrapure water and 20% HPLC grade methanol. An ACE C18-AR analytical column 
(100 mm × 4.6 mm) with 5 μm particle size was used to separate the samples at 30 °C using flowrate of 
0.5 mL min-1. A 5μL injection volume was implemented for the samples; sample runtimes were 5 
minutes and the paracetamol retention time was 1.62 minutes. Paracetamol stock solutions (160 ppm) 
were prepared by dissolving paracetamol (nominally 40 mg) in 5 mL methanol and diluting to volume 
with pH 6.8 dissolution media in a 250 mL volumetric flask. Standards were prepared with the 160 ppm 
 21 
paracetamol stock solution and dissolution media. A typical standard calibration curve is included in 
the supplementary information (Figure S21).  
Scanning Electron Microscope (SEM) imaging of the printed prototype implants were collected by 
cooling the printed bars to -80 °C in a freezer and were cross-sectioned using a scalpel. The samples 
were then mounted on double-sided conductive carbon tape and sputter coated with gold with an Agar 
Sputter Coater. Imaging was carried out on A Hitachi SEM TM3030 Tabletop on a tilt stage. The 
microscope was equipped with a Bruker Scan generator, X Flash SDD detector, Bruker Nano MinSVE 
processor, Deben USB Chamberscope and Deben Sprite HR Stage controller joystick. 
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